Understanding how proteins are modified by ubiquitin in cells
Expanding Mechanistic Insights into Protein Ubiquitylation
This study is looking at how a process called protein ubiquitylation works in our cells, which helps control how proteins behave, and it hopes to find new ways to treat diseases like breast cancer by understanding this process better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10877803 on NIH RePORTER |
What this research studies
This research investigates the process of protein ubiquitylation, which is a crucial cellular regulation mechanism affecting nearly all proteins in a cell. By studying the enzymes involved in this process, the research aims to uncover how different types of ubiquitylation influence protein function and fate under various cellular conditions. The findings could lead to new therapeutic strategies targeting the ubiquitylation machinery, particularly in relation to diseases like breast cancer. Patients may benefit from insights that could inform the development of targeted treatments.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals with a family history of breast cancer or those diagnosed with breast cancer linked to BRCA1 mutations.
Not a fit: Patients with conditions unrelated to protein ubiquitylation or those not affected by breast cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies for diseases associated with dysfunctional protein ubiquitylation, including breast cancer.
How similar studies have performed: Previous research has shown promising results in targeting the ubiquitylation machinery for therapeutic purposes, indicating that this approach has potential for success.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Klevit, Rachel E — University of Washington
- Study coordinator: Klevit, Rachel E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.